9 injections were "processed" and 4 sales surged by more than 100%

A few days ago, the Hunan Provincial Medical Insurance Bureau issued a notice stating that the prices of the online listings within the same listing are quite different (especially in different periods of time), the price and quality are obviously inconsistent, there are many mutual complaints, and the real-name reported prices are inflated.
The 10 medicines were listed on the Internet for price correction and price limit
.
According to data from Minet.
com, the total market size of 10 generic drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 4 billion yuan in 2020
.
List of common names of drugs listed on the Internet for price correction and price limit Note: For sales less than 100 million yuan, use * to indicate the source: Hunan Provincial Medical Insurance Bureau, 9 of the 10 drugs in the Minet database are injections, among which betahistine injection, In 2020, the sales of famotidine injection, ranitidine injection and dihyprophylline injection in public medical institutions in China will all exceed 100 million yuan, and the growth rate will exceed 100%
.
Betahistine injection is an H1 receptor agonist and is used for inner ear vertigo or cerebral arteriosclerosis, ischemic cerebrovascular disease, orthostatic vertigo and tinnitus caused by hypertension.
Sales exceeded 900 million yuan, a year-on-year increase of 110.
69%, and it is likely to exceed 1 billion yuan in 2021
.
The leading company in the first half of 2021 is Shijiazhuang Four Medicines
.
Both famotidine injection and ranitidine injection are H2 receptor antagonists and are representative drugs for the treatment of peptic ulcers.
In 2020, the sales in public medical institutions in China will exceed 500 million yuan and 100 million yuan respectively, with an increase of The rates were 331.
41% and 353.
96% respectively
.
In the first half of 2021, the leading companies for these two injections are Jiangxi Gannan Haixin Pharmaceutical and Anhui Changjiang Pharmaceutical
.
The peak sales of ligustrazine injection for the treatment of ischemic cerebrovascular disease in China's public medical institutions exceeded 1 billion yuan.

.
It is reported that the implementation of drug price correction and price limit listing is an effective means to solve the falsely high drug prices and rectify the order of the pharmaceutical market.
Hunan will implement normalized management after gaining certain experience
.
Hunan has three requirements for the price correction and price limit rules: First, the drugs that have been listed on the procurement platform in the province, and the listed price exceeds 1.
8 times the comparable price of the lowest unit of the same generic name and the same medical insurance dosage form, the excess part will be included in the online listing at 50% The price, and the lowest online price and the actual lowest transaction price of the linkage between the provincial and provincial platforms, take the low value limit of the three to be listed on the Internet
.
Different specifications are determined by conversion according to the price difference rule
.
Among them, if the comparable price of large-capacity injection units is not higher than 4.
5 yuan, it will be linked to the lowest price limit of the national provincial platform and the actual lowest transaction price
.
The second is that other enterprise drugs under the same generic name that are not linked to the provincial procurement platform shall have a comparable price that does not exceed 1.
8 times the lowest unit price of the same generic name and the same medical insurance formulation, and the lowest online price and actual minimum transaction price of the linkage with other provincial platforms.
, take the low value of the three and limit the price to hang on the net
.
The third is that after the price limit is listed according to the above rules, if there are two or more drugs listed on the net with the same generic name, the same medical insurance dosage form and the same specification, the minimum price limit is 1.
8 times, and the drugs listed on the net with more than 1.
8 times the limit price need to take the initiative.
The price of hanging on the Internet will be lowered to no more than 1.
8 times the limit price, otherwise the eligibility for hanging on the Internet will be suspended
.
Hunan officially launched the price limit under the 1.
8 times mechanism, and a new round of drug price cuts has come again
.
Source: Minet database, Hunan Provincial Medical Insurance Bureau